***Click Here to View the Nursing Session E-Syllabus***

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

Breakfast and Non-CME Product Theater

Change Rooms (Exhibit Hall Open)

Welcome and Introductions

How Do I Choose a Therapy for Frontline CLL?

Sequencing Strategies With R/R CLL

Emerging Advancements in CLL: CAR T-Cell Therapies, Bispecific Monoclonal Antibodies, and BTK Degraders

Panel Discussion and Q&A Session

Break (Exhibit Hall Open)

Evolving Use of BTK Inhibitors in Mantle Cell Lymphoma

Expanded Options for Follicular Lymphoma in 2024: A Focus on BTKi, CAR-T, and Bispecific Antibodies

DLBCL: A Risk-Based Approach to Frontline Therapy

Real-World Evidence: Utilizing CAR T-Cell Therapies and Bispecific Antibodies in DLBCL

Hematology Fellows Showdown! #1

Lunch and Concurrent Non-CME Product Theaters

Tailoring CML Treatment Along the Treatment Continuum

Novel Targeted Approaches for MPNs

Minimizing Chemotherapy in ALL

Targeting Anemia in Lower-Risk MDS

Biomarker-Driven Therapy in AML

Newly Diagnosed Multiple Myeloma: Trends in 2024 for Diagnosis and Management

Improved Outcomes for High-Risk Disease in R/R Multiple Myeloma: Balancing Between Efficacy and Safety

Medical Crossfire®: Sequencing Bispecifics and CAR-T Cell Therapies

Hematology Fellows Showdown! #2

Featured CE Symposium: Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Adjourn for the Day

Biomarker Testing and Sequencing Strategies in Colorectal Cancer

Multimodal Approaches to Early-Stage Hepatocellular Carcinoma: A Role for Systemic Therapy?

Advances in Therapy for Esophagogastric Cancers: The Last Year in Review

Evolution in the Treatment and Care of Neuroendocrine Tumors in 2024

Strategies for Treating Leptomeningeal Metastasis

Advancing Molecularly Targeted Therapies for Brain Tumors

Focus on the Most Critical Data of 2024 in Women's Cancers (Ovarian, Endometrial, and Cervical)

Greenspan Lecture Introduction

Greenspan Lecture: Twenty Years of Progress in the Treatment of Non-Small Cell Cancer: Targeted Therapy, Immunotherapy, and the Emergence of Treatment for Early Disease

The Impact of Neoadjuvant Therapy on Local Disease Management

Treatment for HER2-Expressing Breast Cancers: Who Needs More and Who Needs Less?

What's in Your Basket for HR+ Breast Cancer?

Shifting Patient Outcomes: Updates in TNBC

Antibody-Drug Conjugates in Breast Cancer: Do the Targets Matter?

Hot Seat: Breast Cancer Edition

Featured CE Symposium: Homing in on the Role of PSMA in Prostate Cancer – Harnessing the Power of Precision Medicine Through Imaging and Therapy to Individualize Treatment Plans

The Impact of Radioligand Therapy

Targeting the Targets in CRPC: Novel Therapeutic Modalities

Combination Approaches and Novel Therapies for RCC

Urothelial Carcinoma: Biologic Factors That Drive Treatment

Optimizing Multidisciplinary Care for Patients With Head and Neck Cancers in Community Settings

Hot Topics in Skin Cancers: Focus on Melanoma

Management of Advanced Uveal Melanoma in 2024

Lunch and Concurrent Non-CME Product Theater and OncLive® Seminar

EGFR-Mutant Advanced NSCLC: Selecting the Appropriate Frontline Therapy and Beyond

Novel Therapeutic Frontiers in Fusion-Driven Lung Cancers

Exploiting MAPK Activating Amplifications and Mutations: KRAS, MET, BRAF

Are ADCs the New Chemo? HER2, HER3, TROP2, and Beyond

Evolution in Immunotherapy in Advanced NSCLC

Moving Into the Early Stage: Targeted Therapies and Immunotherapy

New Data, New Targets, and New Approaches for SCLC